本研究旨在研究细胞周期进展基因1（CCPG1）在肝细胞癌（HCC）中的临床和预后意义。首先，我们使用癌症基因组图谱和基因型组织表达计划数据库对各种癌症中的CCPG1表达进行了分析。然后，我们使用免疫组化法确定了164例成对的HCC组织和毗邻组织中CCPG1的相对表达水平。分析了CCPG1与HCC的临床病理特征的相关性。使用Cox比例风险模型来确定总生存期（OS）和无病生存期（DFS）的预后因素。CCPG1在HCC组织中的表达低于毗邻非肿瘤肝组织。CCPG1的表达与HCC的肿瘤数量（p = 0.02）和肿瘤分化（p = 0.04）显著相关。HCC患者的CCPG1低表达与较差的OS和DFS相关（p < 0.01）。表示在HCC中的相对低表达与患者术后切除后的预后差相关，提示其可能作为HCC的潜在预后标记。

This study aimed to examine the clinical and prognostic significance of cell-cycle progression gene 1 (CCPG1) in hepatocellular carcinoma (HCC). We firstly analyzed CCPG1 expression in various cancers using The Cancer Genome Atlas and the Genotype-Tissue Expression project databases. The relative expression levels of CCPG1 were determined in 164 paired HCC and adjacent tissues using immunohistochemistry. The correlation between CCPG1 and clinicopathological characteristics of HCC was analyzed. Cox proportional models were used to identify the prognostic factors for overall survival (OS) and disease-free survival (DFS). The expression of CCPG1 was lower in HCC tissues than in adjacent non-tumor liver tissues. The expression of CCPG1 was significantly correlated with tumor number (p = 0.02) and tumor differentiation (p = 0.04) in HCC. Lower expression of CCPG1 in HCC patients was associated with poor OS and DFS (p < 0.01). Relative low expression of CCPG1 in HCC is significantly correlated with the poor prognosis of HCC patients after surgical resection, suggesting its possible role as a potential prognostic marker for HCC.